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1. Arihiro S, Todo K, Koga M, et al. Three-month risk-benefit profile of anticoagulation after stroke with 
atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study. International Journal of 
Stroke. 2016;11(5):565-574. doi:10.1177/1747493016632239
- Researchers looked at 1,137 patients who were hospitalized with ischemic stroke/TIA and 
diagnosed with AF who were started on different anticoagulation, and compared number of 
recurrent ischemic events in those  started on warfarin, dabigatran, rivaroxaban, or apixaban 
2. Diener H-C, Connolly SJ, Ezekowitz MD, et al. Dabigatran compared with warfarin in patients with 
atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY 
trial. The Lancet Neurology. 2010;9(12):1157-1163. doi:10.1016/s1474-4422(10)70274-x
-RCT of 18, 113 AF patients assigned to receive dabigatran or warfarin and followed for 2 
years to assess for recurrent strokes
3. Garcia DA, Wallentin L, Lopes RD, et al. Apixaban versus warfarin in patients with atrial fibrillation 
according to prior warfarin use: Results from the Apixaban for Reduction in Stroke and Other 
Thromboembolic Events in Atrial Fibrillation trial. American Heart Journal. 2013;166(3):549-558. 
doi:10.1016/j.ahj.2013.05.016
- RCT of 18, 201 patients with AF assigned to take apixaban, warfarin, or placebo to test 
efficacy in preventing stroke or systemic embolism
4. Hong K-S, Kwon SU, Lee SH, et al. Rivaroxaban vs Warfarin Sodium in the Ultra-Early Period After 
Atrial Fibrillation–Related Mild Ischemic Stroke. JAMA Neurology. 2017;74(10):1206. 
doi:10.1001/jamaneurol.2017.2161
- RCT of 195 patients with acute cardioembolic strokes secondary to AF designed to determine 
whether rivaroxaban or warfarin was more effective at preventing subsequent strokes
5.  Kanai Y, Oguro H, Tahara N, et al. Analysis of Recurrent Stroke Volume and Prognosis between 
Warfarin and Four Non–Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary 
Prevention of Stroke. Journal of Stroke and Cerebrovascular Diseases. 2018;27(2):338-345. 
doi:10.1016/j.jstrokecerebrovasdis.2017.09.007
- Investigated the volume and number of recurrent strokes in 101 patients with nonvalvular 
atrial fibrillation who were treated with non-vitamin K antagonist oral anticoagulants and 
compared outcomes to patients receiving warfarin 
6. Rost NS, Giugliano RP, Ruff CT, et al. Outcomes With Edoxaban Versus Warfarin in Patients With 
Previous Cerebrovascular Events. Stroke. 2016;47(8):2075-2082. doi:10.1161/strokeaha.116.013540
- RCT of 5,973 AF patients with previous ischemic stroke/TIA designed to investigate and 
compare the efficacy of edoxaban with warfarin in reducing the risk of recurrent stroke 
A literature search was performed in November 2019 using 
Pubmed, Google Scholar, and Academic Search Ultimate to 
compile six articles with the  most relevant and applicable 
research.  Inclusion and exclusion criteria were applied to the 
search in order to compile the most appropriate articles in 
regards to the proposing question. 
● Stroke is the 3rd  leading cause of death and the 1st 
leading cause of long-term disability in the US
● Occurs when blood supply to the brain is interrupted and 
leads to lack of oxygen and nutrients to the brain
● Major risk factor for developing strokes is an abnormal 
heart rhythm called Atrial Fibrillation (AF)
● Stroke patients with a cardioembolic etiology, such as AF 
are at a significantly higher risk of recurrent strokes
● For many years, warfarin has been the anticoagulation 
therapy of choice for recurrent stroke prevention in AF 
patients
● However, with novel oral anticoagulants (NOACs) now on 
the market, there has been a significant deterrence in the 
use of warfarin as stroke prevention therapy 
● Although NOACs have been said to have a more desirable 
side effect profile and are associated with less bleeding 
risks than warfarin, it is still unclear if NOACs are 
superior to warfarin in preventing subsequent 
cardioembolic strokes
Stroke patients diagnosed with Atrial Fibrillation are at a 
significantly increased risk of recurrent strokes secondary to 
this abnormal heart rhythm. The standard first-line treatment 
for atrial fibrillation and stroke prevention includes 
anticoagulation therapy, such as warfarin or novel oral 
anticoagulants.. Novel oral anticoagulants have become the 
preferred choice of anticoagulation in recent years , however 
the question still remains if they are superior at preventing 
recurrent strokes when compared to warfarin.  This research 
hopes to determine in stroke patients diagnosed with atrial 
fibrillation (P), are novel oral anticoagulants (NOACs) (I) 
actually more effective at preventing recurrent strokes (O) 




On the basis of these results, all 6 of the studies 
found that the efficacy of novel oral anticoagulation 
was comparable to that of warfarin. However, only 
two of the studies provided enough statistical 
evidence to determine that novel oral anticoagulation 
was significantly more effective at preventing strokes 
when compared to warfarin (Diener and Garcia.) The 
study conducted by Kanai suggested that 
administering NOACs after a stroke event may not 
reduce infarct recurrence, but it may reduce recurrent 
infarct volume when compared to warfarin.  One 
major deficit across all studies was the timeline and 
duration of intervention. The stroke risk associated 
with AF and prior cerebrovascular accidents is a 
lifelong risk and requires long term follow up and 
management. 
Results
The studies compiled for this meta-analysis all 
demonstrated that warfarin and novel oral 
anticoagulation are comparable in regards to efficacy 
in recurrent stroke prevention. Some research showed 
promising evidence that NOAC patients experienced 
less recurrent ischemic stroke events and lower 
volumes of strokes. Though the evidence is not 
overwhelming enough to determine that NOACs 
should be the drug of choice, it provides insight for 
further research for more definitive data. Future 
studies would have much more power and 
significance if they could obtain a larger, more 
diverse sample population, as well as longer follow 
up. Ultimately, this analysis demonstrated that no one 
anticoagulant can be determined the “gold standard” 
when reducing stroke risk in patients with AF. While 
warfarin and NOACs are comparable in regards to 
efficacy, there are many other factors that must be 
considered on a case by case basis. The choice of 
anticoagulant should be individualized to the patient, 
based on their individual risk factors, comorbidities, 
insurance, and personal preference.
Conclusion
Methods
Study Reduction in 
Recurrent Stroke
Reduction in Major 
Bleeding 
Overall Efficacy and 
Safety of NOAC over 
Warfarin 
1 NS S NS
2 S S S
3 S S S
4 NS NS NS
5 NS NA NA
6 NS S NS
Key: S=  Significant, NS= Not Significant
